C
Cui Dawei
Researcher at Agios Pharmaceuticals
Publications - 9
Citations - 363
Cui Dawei is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Cancer & Pyruvate kinase. The author has an hindex of 3, co-authored 9 publications receiving 215 citations.
Papers
More filters
Journal ArticleDOI
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller,Lemieux Rene M,Erin Artin,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Giovanni Cianchetta,Zhenwei Cai,Ding Zhou,Cui Dawei,Ping Chen,Kimberly Straley,Erica Tobin,Fang Wang,Muriel D. David,Virginie Penard-Lacronique,Cyril Quivoron,Véronique Saada,Stéphane de Botton,Stefan Gross,Lenny Dang,Hua Yang,Luke Utley,Yue Chen,Hyeryun Kim,Shengfang Jin,Zhiwei Gu,Gui Yao,Zhiyong Luo,Xiaobing Lv,Cheng Fang,Liping Yan,Andrew J. Olaharski,Lee Silverman,Scott A. Biller,Shinsan M. Su,Katharine E. Yen +36 more
TL;DR: AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo is reported.
Journal ArticleDOI
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
Zenon D. Konteatis,Erin Artin,Brandon Nicolay,Kimberly Straley,Anil K. Padyana,Lei Jin,Yue Chen,Rohini Narayaraswamy,Shuilong Tong,Feng Wang,Ding Zhou,Cui Dawei,Zhenwei Cai,Zhiyong Luo,Cheng Fang,Huachun Tang,Xiaobing Lv,Raj Nagaraja,Hua Yang,Shinsan M. Su,Zhihua Sui,Lenny Dang,Katharine E. Yen,Janeta Popovici-Muller,Paolo Codega,Carl Campos,Ingo K. Mellinghoff,Scott A. Biller +27 more
TL;DR: Vorasidenib represents a novel dual mIDH1/2 inhibitor that penetrates the brain of several preclinical species and inhibits 2-HG production in glioma tissue by >97% in an orthotopicglioma mouse model.
Patent
Pyruvate kinase modulators and use thereof
Charles Kung,Giovanni Cianchetta,Liu Tao,Anil K. Padyana,Zhihua Sui,Zhenwei Cai,Cui Dawei,Ji Jingjing +7 more
TL;DR: In this paper, methods of using compounds of Formula (I) to modulate PKM2 activity in a subject are described. But these compounds are represented by formula (I): wherein R 1, R 2, L 1, and L 2 are as defined herein.
Patent
Curative active compound and utilization method thereof
TL;DR: In this paper, a method for treating cancers characterized by comprising IDH1/2 mutant alleles was proposed, which includes application of a compound described in the specification to subjects.
Patent
Derivados de lactama útiles como inhibidores de IDH1 mutante
TL;DR: In this paper, a compuesto de formula I o su sal farmaceuticamente aceptable, tautomero, isotopologo or hidrato is presented.